CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 138 enrolled
Drug / intervention
tranexamic acid +1 moredrug
Likely dose
tranexamic acid 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01714336
NCT01714336Phase 4Completed
CompareCT.gov

Is Tranexamic Acid Effective in Limiting Transfusion After Hip Replacement for Femoral Neck Fracture: A Randomized Controlled Trial

Mayo Clinic·interventional·Posted Oct 25, 2012·Updated Nov 14, 2018

In Brief

A Phase 4 clinical trial evaluating tranexamic acid and placebo for Hip Fracture. Completed, enrolled 138 participants across 1 site.

Detailed Summary

Does tranexamic acid improve the perioperative care of those patients treated surgically for hip fracture by decreasing the proportion of patients requiring transfusion and decreasing total perioperative bleeding.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Fracture
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2012
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.7 years ago

Interventions

tranexamic aciddrug

Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.

placebodrug

A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.